Sector Experts

Scott Power

RBS Morgans

Image: Scott Power

Scott Power has spent the last 20 years investing in and researching emerging companies. His first role in the venture capital industry was with QIDC. He joined RBS Morgans Ltd. in 1997. Power sees Australia as a country that produces world-class technology, particularly in the life science sector. Companies like Cochlear Ltd., CSL Ltd. and Resmed have established themselves as market leaders, and a number of up-and-coming companies across the healthcare, life science and technology sectors are poised to follow the leaders, potentially generating significant profits. Power has a wide network of contacts across these sectors that help him identify key trends and developments. Power holds a bachelor's degree in commerce from the University of Queensland and a graduate diploma in applied finance from FINSIA. He is a certified practicing accountant (CPA).




Recent Interviews

Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power (4/17/14) To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement.

Analyst Scott Power Finds the Upside in Biotech Down Under (11/8/12) If you're looking for fresh international names in biotech and medtech, but need the comforts of end markets on U.S. soil, the best ideas of RBS Morgans Ltd. Senior Analyst Scott Power might be for you. In this interview with The Life Sciences Report, Australia-based Power makes a case for important life science names with Australian origins and a U.S. presence that could present investors with huge upside.

Recent Quotes

"IPD has had a transformational event; we increase our price target for the company." (9/5/14) ImpediMed Ltd. - Scott Power, Morgans More >

"ACL enrolled its first patient in CHIME, which is positive news." (6/19/14) Alchemia Ltd. - Scott Power, RBS Morgans More >

"ACL's Phase 3 trial results will be released before Q3/14E." (6/12/14) Alchemia Ltd. - Scott Power, RBS Morgans More >

"With any success in this clinical trial—which is what we're expecting—ACL will be in a position to possibly license HA-irinotecan out." (4/17/14) Alchemia Ltd. - The Life Sciences Report Interview with Scott Powers More >

"GENE is building a sales force and rolling out its BREVAGen test." (11/8/12) Genetic Technologies Ltd. - The Life Sciences Report Interview with Scott Power More >

"We retain our Buy rating for GENE." (8/28/12) Genetic Technologies Ltd. - Scott Power, RBS Morgans More >

"GTG's latest update suggests its sales and reimbursement strategies are gaining some traction." (5/24/12) Genetic Technologies Ltd. - Scott Power, RBS Morgans More >

"GTG continues to make progress; maintain Buy recommendation." (2/28/12) Genetic Technologies Ltd. - Scott Power, RBS Morgans More >



Due to permission requirements, not all quotes are shown.